International Research

Slides:



Advertisements
Similar presentations
Why does ERA Need to Flourish
Advertisements

© 2002 McGraw-Hill Ryerson Ltd.Chapter 14-1 Chapter Fourteen Unions Growth and Incidence Created by: Erica Morrill, M.Ed Fanshawe College.
Western Balkan Technology Fund (WBTF) Initiative
A strategy for a Secure Information Society –
1 A FUTURE EUROPEAN SPORTS POLICY In the name of Autonomy and Specificity By Prof. Michele Colucci, Tilburg University Sports Law and Policy Centre - Rome.
1 SPORT AND COMPETITION LAW AT EU LEVEL Madrid, february 2007 MICHELE COLUCCI
The Benefits and Challenges of Implementation of Basel II in Europe José María Roldán | 27 Sept 2005.
State aid and Structural Funds Carlos Tenreiro DG Competition Brussels 9 April 2003 DG Competition.
Child poverty: a priority for the European Union Committee of the Regions ECOS – 11th Commission meeting 2 December 2012 Paloma Escudero, ED UNICEF Spain.
Policy Research and Innovation Research and Innovation EUROSTARS JOINT PROGRAMME Research and Development programme undertaken by several Member States.
February 16, 2014Ministry of Regional Development - 2 Mid-term assessment of information and publicity measures Commission Regulation (EC) No 1828/2006.
1 A Public Private cooperation for bio-based products Francesco Degli Innocenti Novamont
1 Information meeting Communications Activities in the framework of the MEDA regional Information & Communication Programme targeting Youth in the Mediterranean.
Report on the State of the single market integration 2013 Meeting of the Committee on the Internal Market and Consumer Protection, European Parliament.
Regional Policy Cohesion Policy Legal Package State of play Porto, 29th April 2013 Vicente RODRIGUEZ SAEZ Deputy Head of Unit DG REGIO.D.1 Transnational.
1 European Union Regional Policy – Employment, Social Affairs and Inclusion Addressing challenges in a changing world: -The future Cohesion Policy- Wolfgang.
European Commission Enterprise and Industry Social innovation: How innovation policy can empower people, entrepreneurs and society Henriette van Eijl,
Community Strategic Guidelines DG AGRI, July 2005 Rural Development.
Workshop 4: Using the EU Structural Funds to support Independent Living Ines Bulic European Network on Independent Living Strasbourg Freedom Drive, 9 Sept.
Knowledge intensive companies, IC readiness and Seed Capital New and Improved Activities, Outreach and Support Programs on IP Financing WIPO Forum on intellectual.
Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
European Commission Directorate-General Employment, Social Affairs and Equal Opportunities New Skills for New Jobs Annual Northern Ireland Skills Conference.
Department of Law On the Concept of Relative Market Power CLEEN Workshop June 2008 Lúcio Tomé Féteira, PhD Candidate, EUI (Florence, Italy) –
New EU Forest Strategy and Update on Forest Information and Monitoring
Part Three Markets and Consumer Behavior
International Economics By Robert J. Carbaugh 9th Edition
European Commission Enterprise and Industry # European Standardisation: Proposal for a Regulation Presentation to IMCO – 5 October 2011 European Commission.
10 YEARS AFTER 2004 EU ENLARGEMENT THE BENEFITS & IMPACT OF MODERN RETAIL Brussels, 18 March 2014.
Munich Intellectual Property Law Center (MIPLC) Intellectual Property and Clean Technology in the context of the European Legal Framework Marisa Aranda.
Citizens petitions on shale gas extraction in Bulgaria and Poland Workshop on The exploration and exploitation of shale gas in the European Union and its.
Lima, Peru, 5 December 2013 Smart-Cities: An EU-Wide approach Colette Maloney Head of Unit, Smart Cities and Sustainability, DG CONNECT European Commission.
THE MAIN JURIDICAL ISSUES CONCERNING ROMA/SINTI COMMUNITIES IN ITALY: NO RECOGNITION-NO PROGRESS Prof. Ezio Benedetti International Institute for High.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
1 Laila Castaldo and Ilaria Savoini Brussels, 27 January 2015 “More and better jobs for young people in the commerce sector” Project submitted in relation.
NORMAPME ISO User Guide for European SMEs The essence of.
1 Overview of CSME Issues of Interest Recent Developments and Future Considerations Presented by Desiree Field-Ridley Advisor - Single Market and Sectoral.
The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer.
Workshop ”InDeCS-H: Development of Healthcare Biotechnology SMEs“ 10th September 2009 Budapest Strategy for Hungarian pharmaceutical and biotechnology.
Aurora Plomer, BA, MA, LLB, PhD Professor of Law & Bioethics Director of SIBLE University of Sheffield
The patentability of human pluripotent embryonic stem cells and stem cell lines Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at the.
The legal and ethical dilemma of embryonic stem cells: an impediment to translation in medicine? E. Rial-Sebbag, A. Mahalatchimy, A.M. Duguet.
Innovation, Growth and Patents on CIIs in the EU Federico Etro June 2005.
EVCA Guidelines and Good Practice in the Management of Privately Held Companies in the Private Equity and Venture Capital Industry 28 June 2005 Second.
Internationalisation of European Businesses and EU Economic Diplomacy
1 THE THIRD ENERGY PACKAGE – THE ENERGY COMMUNITY APPROACH Energy Community Secretariat 20 th Forum of the Croatian Energy Association and WEC National.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
Industrial Relations and Social Dialogue in the EMCEF Balatongyörök, April 29, 2006.
European Commission Preparation of the Innovation Union Flagship Initiative European Commission Presentation to ERAC 11 June 2010.
Introductory course on Competition and Regulation Pál Belényesi University of Verona October 2006.
1 Re–use of PSI – Challenges and Opportunities ePSIplus National Meeting Greece 21 May 2008 Athens.
Dr. Christian Schmies 28. June 2013 The Common European Sales Law - Some Policy Questions -
Regional Policy EU Cohesion Policy 2014 – 2020 Proposals from the European Commission.
EU European Territorial Cooperation Legal Package - State of play Vicente RODRIGUEZ SAEZ, DG Regional Policy, European Commission Deputy Head.
A new impetus for Europe's energy efficiency policy Paul Hodson Head of Unit DG Energy, European Commission 09/10/2012.
ESPON Open Seminar, Gödöllö Policy Oriented Panel 5 (22/06/2011) Strategies for competitive, sustainable and secure energy ESPON Applied Research Project.
Enterprise Directorate General European Commission The EU Framework for a Competitive Pharmaceutical Industry for the Benefit of the Patient European.
The Vienna Institute for International Economic Studies Wiener Institut für Internationale Wirtschaftsvergleiche (wiiw) Introduction.
Szilárd Árvay Ministry of Foreign Affairs of Hungary.
Dorota Malgin Legal Adviser Business Innovation and Skills Department, UK Kyiv, 24 February 2016.
Funding and patentability of stem cell research in the European Union - A critical legal review of European legislation Dr. Malene Rowlandson, University.
DG for Regional and Urban Policy European Commission
IP and Knowledge Transfer EC activities
DG AGRI, Unit F6 Bioenergy, biomass, forestry and climatic changes
Boosting Social Enterprises in Europe December 3-4, 2015
Competitiveness of the regional market, importance of statistics and innovations THE ROLE OF RESEARCH CENTERS IN PROMOTING OF RESEARCH Sarajevo, 8th.
THE GOALS OF COMPETITION LAW AND THE ROLE OF LEGAL INSTITUTIONS
Director «Components & Systems»
Outline Background: development of the Commission’s position
IP & the European Court of Human Rights
THE EU LEGAL FRAMEWORK ON EMPLOYEE INVOLVEMENT
Presentation transcript:

International Research Interdisciplinary Ph.D. Programme Research Fellowships International Research Industry Cooperation

Max Weber Multidisciplinary Workshop, EUI Florence, October 10th, 2012 Agnieszka Kupzok, LL.M. IP Impact of Brüstle vs. Greenpeace on the biotechnological sector – first indications Biotech – broad: DNA/RNA : Genomics, pharmacogenomics, gene probes, genetic engineering, DNA/RNA sequencing/synthesis/amplification, gene expression profiling, and use of antisense technology. Proteins and other molecules : Sequencing/synthesis/engineering of proteins and peptides (including large molecule hormones); improved delivery methods for large molecule drugs; proteomics, protein isolation and purification, signaling, identification of cell receptors. Cell and tissue culture and engineering : Cell/tissue culture, tissue engineering (including tissue scaffolds and biomedical engineering), cellular fusion, vaccine/immune stimulants, embryo manipulation. Process biotechnology techniques : Fermentation using bioreactors, bioprocessing, bioleaching, biopulping, biobleaching, biodesulphurisation, bioremediation, biofiltration and phytoremediation. Gene and RNA vectors : Gene therapy, viral vectors. Bioinformatics : Construction of databases on genomes, protein sequences; modelling complex biological processes, including systems biology. Nanobiotechnology : Max Weber Multidisciplinary Workshop, EUI Florence, October 10th, 2012

Overview Context Impact on the European patent system Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Overview Context Impact on the European patent system Importance of patenting in the biotechnological sector Impact on the biotechnological sector Further considerations

Context Highly politicized topic September 18, 2012 Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Context Highly politicized topic September 18, 2012 Legal Affairs Committee of the European Parliament voted to exclude research funding for hESC from Horizon 2020 Framework Program for Research and Innovation. The Brüstle judgement of the CJEU was used as a convincing argument. Today, the Legal Affairs (JURI) Committee of the European Parliament voted to exclude research funding for human embryos and human embryonic stem cells from the Horizon 2020 Framework Programme for Research and Innovation (2014-2020). The amendment to exclude funding was proposed by the rapporteur of the JURI committee, Mr. Borys. The JURI committee is responsible for determining the ethical principles and legal accountability of grants allocated to research. Today’s vote is a critical first step in excluding embryonic stem cell research from European Union funding for research and innovation.

Impact on the European Patent System (I) Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Impact on the European Patent System (I) CJEU opined on the wording of the Biotech Directive EPO adopted the wording of the Biotech Directive in its Implementing Regulations, in 1999. Due to Article 53 EPC, issues affecting “ordre public” are included in the patentability inquiry of the EPO. Combined with Rule 28c of the Implementing Regulations, which implements Art. 6(2)(c) of the Biotech Directive, the interpretation of ECJ influences the patentability in all EPO Member States EPO President 2011: “If the judges rule in favour of a restrictive interpretation of biotech patentability provisions, the EPO will immediately implement it.” Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions It is worth remembering that the EPO is an international organisation and not part of the system of European Institutions. Biotech Directive Article 6.2: On the basis of [the ordre public/morality exclusion] the following, in particular, shall be considered unpatentable: (a) processes for cloning human beings; (b) processes for modifying the germ line genetic identity of human beings; (c) uses of human embryos for industrial or commercial purposes; (d) processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes.

Impact on the European Patent System (II) Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Impact on the European Patent System (II) EPO Member States = EU 27 + 11 States Brüstle v. Greenpeace CJEU’s judgements have an impact on the EU 27. Art. 6(2)(c) included in EPO Implementation Regulations, Rule 28; Together w/Art. 53 (a) EPC Interpretation of Directive 98/44/EC Art. 6(2)(c) 11 Other MS at the EPO are: Albania, Switzerland, Norway, Turkey, Serbia, Croatia, Liechtenstein, Monaco, FYROM, San Marino, Iceland.

EPO Scenarios for the Future – analytical tool Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 EPO Scenarios for the Future – analytical tool 4 Scenarios to approach the changing circumstances: Market Rules – Predominance of Business Who’s World – Predominance of Geopolitics Trees of Knowledge – Predominance of Society Blue Skies – Predominance of Technology Does European law permit patent protection for inventions the preparation of which requires the use of human embryos? WARF/Stem cells (Enlarged Bd, 2009 The EU and the EPC legislators must presumably have been aware of the definitions used in national laws on regulating embryos, and yet chose to leave the term undefined. Given the purpose to protect human dignity and prevent the commercialization of embryos, the Enlarged Board can only presume that ‘embryo’ was not to be given any restrictive meaning in Rule 28 … EPC, as to do so would undermine the intention of the legislator.

The biotechnological sector Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 The biotechnological sector Very innovative, dynamic, and characterized by a large amount of SMEs European Commission estimated in 2011 that the sector contributed 1,55% of gross value added in the EU. Biotechnology is the driving force in innovation processes in several industries (pharmaceuticals, agrochemical, energy, environment) Biotechnology is one of the most research-intensive sectors Protection of research results, especially due to the high portions of revenue invested in R&D plays an important role. biotechnology is increasingly recognized as the next wave in the knowledge-based economy. Biotechnology has been at the core of a number of important developments in the pharmaceutical, agrochemical, energy and environmental sectors. In particular, progress in the field of molecular biology, biotechnology and molecular medicine has highlighted the potential of biotechnology for the pharmaceutical industry. THE FACT THAT IT IS RESEARCH INTENSIVE IMPLIES THAT BIOTECH IS ALSO IS INVESTMENT INTENSIVE. SUCH COMBINATION MAKES THE SECTOR PRONE TO RISKS BECAUSE RESEARCH IMPLIES SPENDING RESOURCES IN THE PRESENT WITH AN UNCERTAIN BENEFIT IN THE FUTURE.

Patenting in the biotechnological sector Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Patenting in the biotechnological sector Allows to secure rights in this sector characterized by long development trajectories. Especially significant, as R&D is characterized by high costs of development and relatively low cost of imitation Is an essential component, when SMEs are established in the sector as spin-offs. Provide a contracting basis between “basic” research in the biotech sector and development of specific products and treatments by pharmaceutical companies. Patents are the main mechanism to secure intellectual property in this high-tech sector with long development trajectories. However, to secure the returns on investments in innovation, firms can A second important point to bear in mind about the biotechnology industry, is that there are generally very high costs for the development of new products and processes, but relatively low costs of imitation. The costs of performing biotechnology research are to be considered in the context of the high risks involved in any research project. It is hard to

Impact of Brüstle v. Greenpeace on the biotechnological sector Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Impact of Brüstle v. Greenpeace on the biotechnological sector Due to the investment intensive R&D in the biotechnological sector, inability to patent is expected to l lead to lower financing, especially seed financing and venture capital Lack of financing may function as a barrier to entry. Lack of proprietary rights may shift the structure of the sector toward “in-house” R&D by big pharmaceutical companies The guarantee to the investors that patents provide comes at a social cost of the society faced with higher prices charged by the company having exclusivity. Lack of patents in the hESC may lead to cheaper medication. Progenitor's and iPSCs Become the Alternative “Where’s the investment money today? It’s in processes and equipment that do embryonic stem cell research,” Grady J. Frenchick, an attorney in the intellectual property department of the law firm Whyte Hirschboeck Dudek S.C., told GEN. “All of that is potentially business to be had, and that’s where much of it lies today.” Frenchick also points to investor interest in “companies and inventions that will essentially be at the next stage of this process.” An example of such a company is Stem Cell Therapeutics (SCT). On May 18, it was awarded a U.S. patent for “platelet-derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells.” The patent covers methods of using PDGF to produce neural progenitor populations that can differentiate into neurons and oligodendrocytes but not astrocytes. Dr. Daley noted, “Harnessing progenitors has considerable practical value. Finding the right recipes for making healthy tissues from pluripotent cells is a major challenge. Progenitors tend to be poised to make disease-relevant tissue, so a focus on deriving progenitors, which typically can be expanded to some degree, is appropriate.” SCT finished last year with a nearly $4.5 million loss, down $196,791 from 2009’s loss. Its working capital dropped from $4.1 million to $2.6 million but received a $2 million boost when SCT completed an equity offering last month. The patent it won last month can only help it reap more. Another way stem cell companies are trying to avoid investor jitters about hESC work is by focusing on induced pluripotent stem cells (iPSCs), reasoning that patients’ bodies would be unlikely to reject their own tissue. For example, on April 7, Cellular Dynamics closed on a $30 million series B private equity round. The firm has raised $100 million since 2004. But iPSCs are still a long way from being widely used in therapeutic development. On May 13, Nature published research by Yang Xu, Ph.D., and a team from University of California, San Diego showing a severe immune rejection in mice after they were implanted with iPSCs derived from their own skin cells. Dr. Xu’s team will study further which cells triggered the reaction, and under what conditions. The work was funded by NIH and CIRM.

However… Patenting is neither a guarantee nor a bar to market success Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 However… Patenting is neither a guarantee nor a bar to market success There are alternatives to patenting in securing benefits from investment: strategic business behavior, lead time. Territorial nature of patent law limits the bar on hESC to the EU + other EPO Member States. Territoriality implies that foreign firms will not obtain patents on hESC-related inventions in the EU, either. Territoriality of patent law also implies that researchers in Europe can apply for patents elsewhere, notably in the United States. Nature of innovation focuses on finding alternatives: Induced Pluripotent Stem Cells (iPSCs) (Nobel Prize 2012) Progenitors Progenitor's and iPSCs Become the Alternative “Where’s the investment money today? It’s in processes and equipment that do embryonic stem cell research,” Grady J. Frenchick, an attorney in the intellectual property department of the law firm Whyte Hirschboeck Dudek S.C., told GEN. “All of that is potentially business to be had, and that’s where much of it lies today.” Frenchick also points to investor interest in “companies and inventions that will essentially be at the next stage of this process.” An example of such a company is Stem Cell Therapeutics (SCT). On May 18, it was awarded a U.S. patent for “platelet-derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells.” The patent covers methods of using PDGF to produce neural progenitor populations that can differentiate into neurons and oligodendrocytes but not astrocytes. Dr. Daley noted, “Harnessing progenitors has considerable practical value. Finding the right recipes for making healthy tissues from pluripotent cells is a major challenge. Progenitors tend to be poised to make disease-relevant tissue, so a focus on deriving progenitors, which typically can be expanded to some degree, is appropriate.” SCT finished last year with a nearly $4.5 million loss, down $196,791 from 2009’s loss. Its working capital dropped from $4.1 million to $2.6 million but received a $2 million boost when SCT completed an equity offering last month. The patent it won last month can only help it reap more. Another way stem cell companies are trying to avoid investor jitters about hESC work is by focusing on induced pluripotent stem cells (iPSCs), reasoning that patients’ bodies would be unlikely to reject their own tissue. For example, on April 7, Cellular Dynamics closed on a $30 million series B private equity round. The firm has raised $100 million since 2004. But iPSCs are still a long way from being widely used in therapeutic development. On May 13, Nature published research by Yang Xu, Ph.D., and a team from University of California, San Diego showing a severe immune rejection in mice after they were implanted with iPSCs derived from their own skin cells. Dr. Xu’s team will study further which cells triggered the reaction, and under what conditions. The work was funded by NIH and CIRM.

Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Conclusions Straightforward securing of investment through patenting is not possible for hESC-based research. Morality and “ordre public” considerations led to a limitation of rules governing technological progress. Alternative perspective could be to observe that EU polity is willing to sacrifice future economic gains in order to protect the dignity of human life. The CJEU judgment affects the biotechnological sector disproportionately strongly, due to the sector’s characteristics and reliance on the patent system. But other observers say the impact may be relatively minor. Europe-based companies can still file for patents in the United States and other countries where such protection is allowed. And any therapies using ES cells will have to go through significant regulatory hurdles before they are approved for use in Europe, notes Alexander Denoon, of the London law firm Lawford Davies Denoon, which specializes in biotechnology patents. "Under the current regulatory framework, it will be virtually impossible to convince a regulator to approve a generic," he said in a statement. "Thus the regulatory protection for approved medicines will be very high."

Thank you for you attention! Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Thank you for you attention! But other observers say the impact may be relatively minor. Europe-based companies can still file for patents in the United States and other countries where such protection is allowed. And any therapies using ES cells will have to go through significant regulatory hurdles before they are approved for use in Europe, notes Alexander Denoon, of the London law firm Lawford Davies Denoon, which specializes in biotechnology patents. "Under the current regulatory framework, it will be virtually impossible to convince a regulator to approve a generic," he said in a statement. "Thus the regulatory protection for approved medicines will be very high." agnieszka.kupzok@yahoo.com

Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 European Parliament

Agnieszka Kupzok Impact of “Brüstle“ on the Biotech sector October 10th, 2012 Bruestle Brüstle v Greenpeace eV (CJEU, 2011) 26. [‘Human embryo’] must be regarded … as designating an autonomous concept of European Union law… 29. [U]nlike Article 6(1) of the Directive, which allows the … Member States a wide discretion in applying the [public ordre/morality] exclusion from patentability … Article 6(2) allows the Member States no discretion with regard to the unpatentability of the processes and uses which it sets out, since [its] purpose is to delimit [Article 6(1)]… 34. The … European Union legislature intended to exclude any possibility of patentability where respect for human dignity could thereby be affected. It follows that the concept of ‘human embryo’ … must be understood in a wide sense. 45. That interpretation is … identical to that adopted by the Enlarged Board of Appeal of the European Patent Office [in Warf]… The goal of efficiency in Chicago law and economics manifests itself in the normative prescription that rights should be assigned in a way that maximizes the wealth of society.